Work

Dual PD‐1/LAG‐3 Blockade in Breast Cancer: Navigating Benefit and Risk

Year: 2026

Type: article

Abstract: The addition of immune checkpoint inhibitors to neoadjuvant chemotherapy has reshaped the treatment landscape for earlystage triple-negative breast cancer (TNBC).However, for hormone receptor-positive, HER2-negative (HR + /HER2 -) breast cancer, the most common subtype, the benefits of immunotherapy have remained limited.The I-SPY2 trial, recently published in JAMA Oncology, evaluated the combination of the anti-PD-1 antibody cemiplimab and the anti-LAG-3 antibody fianlimab (the PCF regimen) in early-stage high-risk HER2-negative breast cancer [1].The results showed remarkable efficacy alongside safety concerns that warrant careful consideration.

Source: Cancer Innovation

DOI: 10.1002/cai2.70088

Authors: Kaixiang Feng, Fanxiang Yin, Mengting Chen, Zongbi Yi

Institutions: First Affiliated Hospital of Zhengzhou University, University of Southampton, Chinese Academy of Medical Sciences & Peking Union Medical College

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,700